Meeting
2017 ASCO Annual Meeting
Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head and neck.
Authors
John T. Vetto
Knight Cancer Institute, Oregon Health & Science University, Portland, OR
John T. Vetto , Sancy Ann Leachman , Brooke Middlebrook , Kyle R. Covington , Jeffrey D. Wayne , Pedram Gerami , Jonathan S. Zager
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9576)
DOI
10.1200/JCO.2017.35.15_suppl.9576
Abstract #
9576
Poster Bd #
184
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB).
First Author: David H. Lawson
Poster
2016 ASCO Annual Meeting
Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients.
First Author: Jonathan S. Zager
Poster
2022 ASCO Annual Meeting
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
First Author: Dirk Schadendorf
Poster
2022 ASCO Annual Meeting
MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma.
First Author: Tina J. Hieken